Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: A randomized placebo-controlled trial

Pharmacotherapy

Volumn 33, Issue 8, 2013, Pages 817-826

  Derosa, Giuseppe ^a   Franzetti, Ivano G ^b   Querci, Fabrizio ^c   Carbone, Anna ^d   Ciccarelli, Leonardina ^e   Piccinni, Mario N ^f   Fogari, Elena ^a   Maffioli, Pamela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b OSPEDALE DI CIRCOLO   (Italy)

^c Alzano Lombardo   (Italy)

^d Hospital Center of Diabetes   (Italy)

^e RSA Villa Mafalda   (Italy)

^f Fondazione Ospedale Della Caritá   (Italy)

Author keywords

Chemerin; Exenatide; Glycemic control; Inflammation; Metformin; Resistin; Vaspin

Indexed keywords

ARGININE; C PEPTIDE; CHEMERIN; EXENDIN 4; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; PROINSULIN; RESISTIN; VASPIN;

ADULT; ANALYTICAL PARAMETERS; B LYMPHOCYTE; BLOATING; BODY MASS; BODY WEIGHT; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; ITALY; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PROINSULIN TO FASTING PLASMA INSULIN RATIO; RANDOMIZED CONTROLLED TRIAL; REVIEW; VOMITING;

EID: 84885231257     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1301     Document Type: Review

References (37)

1. Jackson MB, Ahima RS. Neuroendocrine and metabolic effects of adipocyte-derived hormones. Clin Sci (Lond) 2006;110:143-52.
2. Derosa G, D'Angelo A, Salvadeo SA, et al. Oral glucose tolerance test effects on endothelial inflammation markers in healthy subjects and diabetic patients. Horm Metab Res 2010;42:8-13.
3. Derosa G, D'Angelo A, Salvadeo SA, et al. Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects. Microvasc Res 2010;79:144-9.
4. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006;83:456S-60S.
5. Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 2001;322:15-8.
6. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
7. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.
8. Derosa G, Maffioli P. Effects of thiazolidinediones and sulfonylureas in patients with diabetes. Diabetes Technol Ther 2010;12:491-501.
9. Derosa G, Tinelli C, Maffioli P. Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. Diabetes Obes Metab 2009;11:1091-9.
10. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-12.
11. Derosa G, Maffioli P. Dipeptidyl peptidase-4 inhibitors: 3 years of experience. Diabetes Technol Ther 2012;14:350-64.
12. Derosa G, Maffioli P. GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy. Curr Clin Pharmacol 2012;7:214-28.
13. Triplitt CL. New technologies and therapies in the management of diabetes. Am J Manag Care 2007;13:547-54.
14. Derosa G, Maffioli P, Salvadeo SA, et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol Ther 2010;12:233-40.
15. Derosa G, Putignano P, Bossi AC, et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. Eur J Pharmacol 2011;666:251-6.
16. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136.
17. Lichtenstein AH, Appel LJ, Brands M, et al. Summary of American Heart Association Diet and Lifestyle Recommendations Revision 2006. Arterioscler Thromb Vasc Biol 2006;26:2186-91.
18. Derosa G, Ragonesi PD, Carbone A, et al. Vildagliptin action on some adipocytokines levels in type 2 diabetic patients: a 12 months, placebo-controlled study. Expert Opin Pharmacother 2012;13:2581-91.
19. Hida K, Wada J, Eguchi J, et al. Visceral adipose tissuederived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005;102:10610-5.
20. Winer BJ. Statistical principles in experimental design. 2nd ed. New York: McGraw-Hill, 1971.
21. Bunck MC, Diamant M, Corner A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009;32:762-8.
22. Derosa G, Mereu R, D'Angelo A, et al. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin. J Clin Pharm Ther 2010;35:565-79.
23. Derosa G, D'Angelo A, Salvadeo SA, et al. Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment. Biomed Pharmacother 2009;63:723-33.
24. Derosa G, Maffioli P, D'Angelo A, Fogari E, Bianchi L, Cicero AF. Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study. J Diabetes Complications 2011;25:258-66.
25. Derosa G, Maffioli P, Ferrari I, et al. Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. Eur J Pharmacol 2011;651:240-50.
26. Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003;198:977-85.
27. Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007;148:4687-94.
28. Goralski KB, McCarthy TC, Hanniman EA, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007;282:28175-88.
29. Youn BS, Kloting N, Kratzsch J, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008;57:372-7.
30. El-Mesallamy HO, Kassem DH, El-Demerdash E, Amin AI. Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism 2011;60:63-70.
31. Azuma K, Oguchi S, Matsubara Y, et al. Novel resistin promoter polymorphisms: association with serum resistin level in Japanese obese individuals. Horm Metab Res 2004;36:564-70.
32. Bouchard L, Weisnagel SJ, Engert JC, et al. Human resistin gene polymorphism is associated with visceral obesity and fasting and oral glucose stimulated C-peptide in the Quebec Family Study. J Endocrinol Invest 2004;27:1003-9.
33. McTernan PG, Fisher FM, Valsamakis G, et al. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 2003;88:6098-106.
34. Ohmori R, Momiyama Y, Kato R, et al. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol 2005;46:379-80.
35. Tan BK, Chen J, Farhatullah S, et al. Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes 2009;58:1971-7.
36. Cechin SR, Perez-Alvarez I, Fenjves E, et al. Anti-inflammatory properties of exenatide in human pancreatic islets. Cell Transplant 2012;21:633-48.
37. Chakaroun R, Raschpichler M, Kloting N, et al. Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity. Metabolism 2012;61:706-14.